Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention

References

• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi: 10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–328. doi: 10.1111/jth.12485
   PubMed Web of Science ®Google Scholar
• Rosovsky RP, Kline-Rogers E, Lake L, et al. Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel. Am J Med. 2023;136(6):523–533. doi: 10.1016/j.amjmed.2023.01.010
   PubMed Web of Science ®Google Scholar
• Moret C, Acosta-Isaac R, Mojal S, et al. Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: critical appraisal of real-world data. PLOS ONE. 2023;18(2):e0279297. doi: 10.1371/journal.pone.0279297
   PubMed Web of Science ®Google Scholar
• Haymart B, Barnes GD, Kong X, et al. Comparison of patient outcomes before and after switching from warfarin to a direct oral anticoagulant based on time in therapeutic range guideline recommendations. JAMA Netw Open. 2022;5(7):e2222089. doi: 10.1001/jamanetworkopen.2022.22089
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405
   PubMed Web of Science ®Google Scholar
• Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230–2239. doi: 10.1182/blood-2018-06-848747
   PubMed Web of Science ®Google Scholar
• Rizzo A, Donzelli S, Girgenti V, et al. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res. 2017;36(1):76. doi: 10.1186/s13046-017-0546-9
   PubMedGoogle Scholar
• Stockis A, Watanabe S, Scheen AJ. Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol. 2015;55(5):543–548. doi: 10.1002/jcph.446
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66(1):71–75. doi: 10.1111/j.1365-2125.2008.03158.x
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Markowitz JS, et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. 2006;317(2):850–857. doi: 10.1124/jpet.105.098541
   PubMed Web of Science ®Google Scholar
• Auzmendi J, Palestro P, Blachman A, et al. Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and astrocytes under hypoxic conditions. Front Behav Neurosci. 2020;14:32. doi: 10.3389/fnbeh.2020.00032
   PubMed Web of Science ®Google Scholar
• Nasrin S, Watson CJW, Perez-Paramo YX, et al. Cannabinoid metabolites as inhibitors of Major Hepatic CYP450 Enzymes, with implications for Cannabis-Drug Interactions. Drug Metab Dispos. 2021;49(12):1070–1080. doi: 10.1124/dmd.121.000442
   PubMedGoogle Scholar
• Teichmann E, Blessing E, Hinz B. Non-psychoactive phytocannabinoids inhibit inflammation-related changes of human coronary artery smooth muscle and endothelial cells. Cells. 2023;12(19):2389. doi: 10.3390/cells12192389
   PubMed Web of Science ®Google Scholar
• Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol. 1989;41(10):705–709. doi: 10.1111/j.2042-7158.1989.tb06345.x
   PubMed Web of Science ®Google Scholar
• Walsh SK, Hepburn CY, Kane KA, et al. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol. 2010;160(5):1234–1242. doi: 10.1111/j.1476-5381.2010.00755.x
   PubMed Web of Science ®Google Scholar
• Brueck S, Bruckmueller H, Wegner D, et al. Transcriptional and Post-transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in healthy human subjects after chronic treatment with rifampin and Carbamazepine. Mol Pharm. 2019;16(9):3823–3830. doi: 10.1021/acs.molpharmaceut.9b00458
   PubMedGoogle Scholar
• Lombardo L, Pellitteri R, Balazy M, et al. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res. 2008;5(2):82–92. doi: 10.2174/156720208784310196
   PubMed Web of Science ®Google Scholar
• Yang HW, Liu HY, Liu X, et al. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett. 2008;434(3):299–303. doi: 10.1016/j.neulet.2008.01.071
   PubMed Web of Science ®Google Scholar
• Järvinen E, Hammer HS, Pötz O, et al. 3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction. Clin Pharmacol Ther. 2023;113(6):1284–1294. doi: 10.1002/cpt.2887
   PubMed Web of Science ®Google Scholar
• Hole K, Wollmann BM, Nguyen C, et al. Comparison of CYP3A4-inducing capacity of enzyme-inducing antiepileptic drugs using 4β-hydroxycholesterol as biomarker. Ther Drug Monit. 2018;40(4):463–468. doi: 10.1097/FTD.0000000000000518
   PubMed Web of Science ®Google Scholar
• Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61(1):58–69. doi: 10.1111/j.1365-2125.2005.02507.x
   PubMed Web of Science ®Google Scholar
• Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A induction predicts P-glycoprotein Induction; part 2: prediction of decreased substrate exposure after Rifabutin or carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191–1198. doi: 10.1002/cpt.1072
   PubMed Web of Science ®Google Scholar
• Vlase L, Neag M, Popa A, et al. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J Clin Pharm Ther. 2011;36(2):225–229. doi: 10.1111/j.1365-2710.2010.01170.x
   PubMed Web of Science ®Google Scholar
• Gjestad C, Huynh DK, Haslemo T, et al. 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? Br J Clin Pharmacol. 2016;81(2):269–276. doi: 10.1111/bcp.12833
   PubMed Web of Science ®Google Scholar
• Xiao W, Zhou K, Yang M, et al. Carbamazepine induces platelet apoptosis and thrombocytopenia through protein kinase a. Front Pharmacol. 2021;12:749930. doi: 10.3389/fphar.2021.749930
   PubMed Web of Science ®Google Scholar
• Rajtar G, Zółkowska D, Czechowska G, et al. Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study. Epilepsy Res. 2001;43(1):59–66. doi: 10.1016/S0920-1211(00)00176-5
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Hirai H, Iino M, et al. Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology. 2009;56(2):499–506. doi: 10.1016/j.neuropharm.2008.10.003
   PubMed Web of Science ®Google Scholar
• Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899–911. doi: 10.1111/cts.13204
   PubMed Web of Science ®Google Scholar
• Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340–353. doi: 10.1002/j.1875-9114.2012.01028.x
   PubMed Web of Science ®Google Scholar
• Vrzal R, Kubesova K, Pavek P, et al. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. Toxicol Lett. 2010;193(2):183–188. doi: 10.1016/j.toxlet.2010.01.004
   PubMed Web of Science ®Google Scholar
• Rajtar G, Zółkowska D, Kleinrok Z. Effect of diazepam and clonazepam on the function of isolated rat platelet and neutrophil. Med Sci Monit. 2002;8:I37–44.
   Google Scholar
• Falcão A, Pinto R, Nunes T, et al. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res. 2013;106(1–2):244–249. doi: 10.1016/j.eplepsyres.2013.04.009
   PubMed Web of Science ®Google Scholar
• Egnell AC, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther. 2003;305(3):1251–1262. doi: 10.1124/jpet.102.047530
   PubMed Web of Science ®Google Scholar
• Martin P, Czerwiński M, Limaye PB, et al. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. Pharmacol Res Perspect. 2022;10(3):e00959. doi: 10.1002/prp2.959
   PubMed Web of Science ®Google Scholar
• Barradas MA, Mikhailidis DP, Dandona P. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. Br J Clin Pharmacol. 1983;16(4):459. doi: 10.1111/j.1365-2125.1983.tb02198.x
   PubMed Web of Science ®Google Scholar
• Russell GR, Phelps SJ, Shelton CM, et al. Impact of Drug Interactions on Clobazam and N-Desmethylclobazam concentrations in pediatric patients with epilepsy. Ther Drug Monit. 2018;40(4):452–462. doi: 10.1097/FTD.0000000000000530
   PubMed Web of Science ®Google Scholar
• Ranzino AM, Sorrells KR, Manor SM. Possible acute thrombocytopenia post esomeprazole and hydantoin coadministration. J Pharm Pract. 2010;23(2):140–143. doi: 10.1177/0897190009341308
   PubMedGoogle Scholar
• Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundamemntal Clinical Pharma. 2000;14(4):301–319. doi: 10.1111/j.1472-8206.2000.tb00411.x
   PubMed Web of Science ®Google Scholar
• Pan CF, Shen MY, Wu CJ, et al. Inhibitory mechanisms of gabapentin, an antiseizure drug, on platelet aggregation. J Pharm Pharmacol. 2007;59(9):1255–1261. doi: 10.1211/jpp.59.9.0010
   PubMed Web of Science ®Google Scholar
• Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54(9):901–914. doi: 10.1007/s40262-015-0276-0
   PubMed Web of Science ®Google Scholar
• Wang-Tilz Y, Tilz C, Wang B, et al. Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. Epilepsia. 2006;47(2):233–239. doi: 10.1111/j.1528-1167.2006.00414.x
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–255. doi: 10.1111/j.1365-2125.2005.02529.x
   PubMed Web of Science ®Google Scholar
• Siniscalchi A, Gallelli L, Calabrò G, et al. Phenobarbital/Lamotrigine coadministration–induced blood dyscrasia in a patient with epilepsy. Ann Pharmacother. 2010;44(12):2031–2034. doi: 10.1345/aph.1P335
   PubMed Web of Science ®Google Scholar
• Moerman L, Wyffels L, Slaets D, et al. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide. Epilepsy Res. 2011;94(1–2):18–25. doi: 10.1016/j.eplepsyres.2010.12.013
   PubMed Web of Science ®Google Scholar
• Ucar HK, Sarigecili E, Bilen S, et al. Short-term and long-term effects of Levetiracetam Monotherapy on Hematological Parameters in children with idiopathic epilepsy. Sisli Etfal Hastan Tip Bul. 2023;57(1):46–53. doi: 10.14744/SEMB.2022.98523
   PubMed Web of Science ®Google Scholar
• Sato M, Hirakata H, Ikeda M, et al. Effects of barbiturates on human platelet aggregation differ depending on their chemical structures. Can J Physiol Pharmacol. 2003;81(8):806–814. doi: 10.1139/y03-075
   PubMed Web of Science ®Google Scholar
• Murayama N, Shimada M, Yamazoe Y, et al. Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P450 induction. Arch Biochem Biophys. 1996;328(1):184–192. doi: 10.1006/abbi.1996.0159
   PubMed Web of Science ®Google Scholar
• Ji J, Li G, Ma Y, et al. Expression of multidrug resistance genes in peripheral blood of patients with refractory epilepsy and the reverse effect of Oxcarbazepine on its expression. Iran J Public Health. 2018;47(1):40–48.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi PF, Bendoni L, et al. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit. 1993;15(1):39–42. doi: 10.1097/00007691-199302000-00007
   PubMed Web of Science ®Google Scholar
• Ogbebor O, Agrawal A, Yegneswaran B. Lesson of the month 1: to stop a fit, but swinging low. Clin Med. 2018;18(3):256–258. doi: 10.7861/clinmedicine.18-3-256
   PubMed Web of Science ®Google Scholar
• Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016;82(2):422–430. doi: 10.1111/bcp.12951
   PubMed Web of Science ®Google Scholar
• Goldstein R, Jacobs AR, Zighan L, et al. Interactions between direct oral anticoagulants (DOACs) and Antiseizure Medications: potential implications on DOAC treatment. CNS Drugs. 2023;37(3):203–214. doi: 10.1007/s40263-023-00990-0
   PubMed Web of Science ®Google Scholar
• Almuhanna RA, Muddassir R, Almaghrabi M, et al. Perampanel-induced, new-onset thrombocytopenia in a patient with refractory seizures: a case report. Cureus. 2023;15:e37781. doi: 10.7759/cureus.37781
   PubMed Web of Science ®Google Scholar
• Alvariza S, Fagiolino P, Vázquez M, et al. Chronic administration of phenytoin induces efflux transporter overexpression in rats. Pharmacol Rep. 2014;66(6):946–951. doi: 10.1016/j.pharep.2014.06.007
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13–18. doi: 10.1111/j.0013-9580.2004.455003.x
   PubMed Web of Science ®Google Scholar
• Qu C, Xie Y, Qin F, et al. Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. Int J Clin Pharm. 2014;36(6):1138–1140. doi: 10.1007/s11096-014-0026-7
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43(4):365–385. doi: 10.1046/j.1528-1157.2002.13001.x
   PubMed Web of Science ®Google Scholar
• Tompson DJ, Crean CS, Buraglio M, et al. Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study. Clin Pharmacol. 2014;6:149–159. doi: 10.2147/CPAA.S64131
   PubMedGoogle Scholar
• Ekiciler A, Chen WLK, Bo Y, et al. Quantitative cytochrome P450 3A4 induction risk assessment using human hepatocytes complemented with pregnane X receptor-activating profiles. Drug Metab Dispos. 2023;51(3):276–284. doi: 10.1124/dmd.122.001132
   PubMed Web of Science ®Google Scholar
• Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490–504. doi: 10.1016/S0009-9236(97)90044-8
   PubMed Web of Science ®Google Scholar
• Chen Q, Xin M, Wang L, et al. Inhibition of LDHA to induce eEF2 release enhances thrombocytopoiesis. Blood. 2022;139(19):2958–2971. doi: 10.1182/blood.2022015620
   PubMed Web of Science ®Google Scholar
• Pita-Calandre E. Implicaciones clínicas de la farmacología y la farmacocinética de la tiagabina. RevNeurol. 1999;28(3):337–339. doi: 10.33588/rn.2803.98523
   Google Scholar
• Nallani SC, Glauser TA, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003;44(12):1521–1528. doi: 10.1111/j.0013-9580.2003.06203.x
   PubMed Web of Science ®Google Scholar
• Polimeni G, Grugno R, Vitetta A, et al. A case of topiramate-induced epistaxis. Curr Drug Saf. 2009;4(3):207–208. doi: 10.2174/157488609789007001
   PubMedGoogle Scholar
• Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006;149(3):250–260. doi: 10.1038/sj.bjp.0706830
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7):1032–1041. doi: 10.1124/dmd.106.014456
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Kivistö KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52(5):547–553. doi: 10.1046/j.0306-5251.2001.01474.x
   PubMed Web of Science ®Google Scholar
• Bartels M, Govers A, Polak R, et al. Megakaryocyte lineage development is controlled by modulation of protein acetylation. PLOS ONE. 2018;13(4):e0196400. doi: 10.1371/journal.pone.0196400
   PubMed Web of Science ®Google Scholar
• Davidson DC, Hirschman MP, Spinelli SL, et al. Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol. 2011;186(1):584–591. doi: 10.4049/jimmunol.1001911
   PubMed Web of Science ®Google Scholar
• Kis B, Szupera Z, Mezei Z, et al. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia. 1999;40(3):307–310. doi: 10.1111/j.1528-1157.1999.tb00709.x
   PubMed Web of Science ®Google Scholar
• Raza M, Al-Shabanah OA. Effect of vigabatrin on contractile response to arachidonic acid and prostaglandins in smooth muscle preparations and platelet aggregation in experimental laboratory animals. Pharmacol Res. 2003;47:477–483. doi: 10.1016/S1043-6618(03)00045-8
   PubMed Web of Science ®Google Scholar
• Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res. 2007;75(2–3):75–83. doi: 10.1016/j.eplepsyres.2007.04.007
   PubMed Web of Science ®Google Scholar
• Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. Clin Drug Invest. 2012;32(8):533–538. doi: 10.1007/BF03261904
   PubMed Web of Science ®Google Scholar
• Wong Y, Yeh C, Thyrum P. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001;21(1):89–93. doi: 10.1097/00004714-200102000-00016
   PubMed Web of Science ®Google Scholar
• Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. doi: 10.1136/bmj.i2868
   PubMed Web of Science ®Google Scholar
• Wang CL, Wu VC, Chang KH, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):147–154. doi: 10.1093/ehjcvp/pvz035
   PubMed Web of Science ®Google Scholar
• Forbes HL, Polasek TM. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Therapeutic Advances In Drug Safety. 2017;8(10):319–328. doi: 10.1177/2042098617719815
   PubMed Web of Science ®Google Scholar
• Harskamp RE, Himmelreich JCL, Wong GWM, et al. Prescription patterns of direct oral anticoagulants and concomitant use of interacting medications in the Netherlands. Neth Heart J. 2021;29(9):451–459. doi: 10.1007/s12471-021-01612-4
   PubMed Web of Science ®Google Scholar
• Giustozzi M, Mazzetti M, Paciaroni M, et al. Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation. Clin Drug Investig. 2021;41(1):43–51. doi: 10.1007/s40261-020-00982-8
   PubMed Web of Science ®Google Scholar
• Ip BY, Ko H, Wong GL, et al. Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis. CNS Drugs. 2022;36(12):1313–1324. doi: 10.1007/s40263-022-00971-9
   PubMed Web of Science ®Google Scholar
• Perlman A, Hochberg-Klein S, Choshen Cohen L, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis. 2019;47(4):590–595. doi: 10.1007/s11239-018-01804-7
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC). Oslo: Norwegian Institute of Public Health; 2015 [cited 2023 Nov 21]. Available from: https://www.whocc.no/atc_ddd_index
   Google Scholar
• Acton EK, Gelfand MA, Hennessy S, et al. Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018. Epilepsy Behav. 2020;113:107550. doi: 10.1016/j.yebeh.2020.107550
   PubMed Web of Science ®Google Scholar
• Taha M, Li W, Schmidt CM, et al. The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: a systematic review. Epilepsy Res. 2020;162:106304. doi: 10.1016/j.eplepsyres.2020.106304
   PubMed Web of Science ®Google Scholar
• Galgani A, Palleria C, Iannone LF, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067. doi: 10.3389/fneur.2018.01067
   PubMed Web of Science ®Google Scholar
• Candeloro M, Carlin S, Shapiro MJ, et al. Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review. Res Pract Thromb Haemost. 2023;7(3):100137. doi: 10.1016/j.rpth.2023.100137
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676. doi: 10.1093/europace/euab065
   PubMed Web of Science ®Google Scholar
• Perlman A, Wanounou M, Goldstein R, et al. Ischemic and thrombotic events associated with concomitant xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA adverse event reporting system (FAERS). CNS Drugs. 2019;33(12):1223–1228. doi: 10.1007/s40263-019-00677-5
   PubMed Web of Science ®Google Scholar
• Perlman A, Goldstein R, Choshen Cohen L, et al. Effect of Enzyme-Inducing Antiseizure Medications on the risk of sub-therapeutic concentrations of direct oral anticoagulants: a retrospective cohort study. CNS Drugs. 2021;35(3):305–316. doi: 10.1007/s40263-021-00795-z
   PubMed Web of Science ®Google Scholar
• Sennesael AL, Larock AS, Hainaut P, et al. The impact of strong inducers on direct oral anticoagulant levels. Am J Med. 2021;134(10):1295–1299. doi: 10.1016/j.amjmed.2021.06.003
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254–267. doi: 10.2174/157015910792246254
   PubMed Web of Science ®Google Scholar
• Stöllberger C, Finsterer J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res. 2016;126:98–101. doi: 10.1016/j.eplepsyres.2016.06.003
   PubMed Web of Science ®Google Scholar
• Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110(6):1526–1536. doi: 10.1002/cpt.2369
   PubMed Web of Science ®Google Scholar
• Chin PK, Wright DF, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D. 2014;14(2):113–123. doi: 10.1007/s40268-014-0045-9
   PubMedGoogle Scholar
• King PK, Stump TA, Walkama AM, et al. Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke. Ann Pharmacother. 2018;52(6):605–606. doi: 10.1177/1060028018759938
   PubMed Web of Science ®Google Scholar
• Zhou M, Leonard CE, Brensinger CM, et al. Pharmacoepidemiologic screening of potential oral anticoagulant drug interactions leading to thromboembolic events. Clin Pharmacol Ther. 2020;108(2):377–386. doi: 10.1002/cpt.1845
   PubMed Web of Science ®Google Scholar
• Ranzato F, Roberti R, Deluca C, et al. Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective. Neurol Sci. 2024;45(1):277–288. doi: 10.1007/s10072-023-06992-6
   PubMed Web of Science ®Google Scholar
• Dagan G, Perlman A, Hochberg-Klein S, et al. Managing direct oral anticoagulants in patients with antiepileptic medication. Can J Cardiol. 2018;34(11):.e1534.1–.e1534.3. doi: 10.1016/j.cjca.2018.08.001
   Web of Science ®Google Scholar
• Caviness LA, Wassell KM, Howard-Thompson A. Acute elevation of liver function test values following concomitant administration of dabigatran and primidone. Am J Health Syst Pharm. 2022;79(15):1250–1254. doi: 10.1093/ajhp/zxac054
   PubMed Web of Science ®Google Scholar
• Sáez-Torres de Vicente M, Martínez Puig P, Valverde Toresano L. Ictus isquémico por posible interacción de rivaroxabán con primidona en paciente con fibrilación auricular. Medicina Clínica. 2021;156(5):255–256. doi: 10.1016/j.medcli.2019.12.024
   PubMed Web of Science ®Google Scholar
• Chang SH, Chou IJ, Yeh YH, et al. Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of Major bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250–1259. doi: 10.1001/jama.2017.13883
   PubMed Web of Science ®Google Scholar
• Candeloro M, Eikelboom JW, Chan N, et al. Carbamazepine, phenytoin, and oral anticoagulants: drug-drug interaction and clinical events in a retrospective cohort. Res Pract Thromb Haemost. 2022;6(2):e12650. doi: 10.1002/rth2.12650
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Northup A, Johnson D, et al. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy. 2016;36(2):e5–7. doi: 10.1002/phar.1698
   PubMed Web of Science ®Google Scholar
• Hager N, Bolt J, Albers L, et al. Development of left atrial thrombus after coadministration of dabigatran etexilate and phenytoin. Can J Cardiol. 2017;33(4):.e554.13–.e554.14. doi: 10.1016/j.cjca.2016.10.022
   Web of Science ®Google Scholar
• Becerra AF, Amuchastegui T, Tabares AH. Decreased rivaroxaban levels in a patient with cerebral vein thrombosis receiving phenytoin. Case Rep Hematol. 2017;2017:4760612. doi: 10.1155/2017/4760612
   PubMed Web of Science ®Google Scholar
• Laureano M, Crowther M, Eikelboom J, et al. Measurement of Dabigatran Drug Levels to manage patients taking interacting drugs: a case report. Am J Med. 2016;129(10):e247–8. doi: 10.1016/j.amjmed.2016.06.017
   PubMed Web of Science ®Google Scholar
• Bortz H, Corallo CE, Tran H. Increasing understanding regarding the risk of concomitant use of carbamazepine and direct oral anticoagulants. J Pharm Pract. 2019;32(2):123–125. doi: 10.1177/0897190018786837
   PubMed Web of Science ®Google Scholar
• Burden T, Thompson C, Bonanos E, et al. Lesson of the month 2: pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. Clin Med. 2018;18(1):103–105. doi: 10.7861/clinmedicine.18-1-103
   PubMed Web of Science ®Google Scholar
• Risselada AJ, Visser MJ, van Roon E. Longembolie door interactie tussen rivaroxaban en carbamazepine [Pulmonary embolism due to interaction between rivaroxaban and carbamazepine]. Ned Tijdschr Geneeskd. 2013;157(52):A6568.
   PubMedGoogle Scholar
• Stöllberger C, Finsterer J. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. Neurol Neurochir Pol. 2017;51(2):194–196. doi: 10.1016/j.pjnns.2017.01.010
   PubMed Web of Science ®Google Scholar
• Abou Kaoud M, Nissan R, Segev A, et al. Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study. CNS Drugs. 2023;37(12):1111–1121. doi: 10.1007/s40263-023-01052-1
   PubMed Web of Science ®Google Scholar
• Chadha A, Lopaschuk D, Ackman ML, et al. The problem with predictions: a cautionary tale of empirically adjusting apixaban dosing with carbamazepine. CJC Open. 2022;4(4):435–438. doi: 10.1016/j.cjco.2021.12.012
   PubMedGoogle Scholar
• Bungard TJ, Roberts RN. Carbamazepine induction impacting apixaban concentrations: a case report. CJC Open. 2020;2:423–425. doi: 10.1016/j.cjco.2020.04.009
   PubMedGoogle Scholar
• Evanger N, Szkotak A, Stang L, et al. Apixaban concentration with and without coadministration of carbamazepine: a case with No apparent interaction. Can J Hosp Pharm. 2017;70(6):463–467. doi: 10.4212/cjhp.v70i6.1714
   PubMedGoogle Scholar
• Di Gennaro L, Lancellotti S, De Cristofaro R, et al. Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. J Thromb Thrombolysis. 2019;48(3):528–531. doi: 10.1007/s11239-019-01866-1
   PubMed Web of Science ®Google Scholar
• Robinson ZS, Arvin JP, Madding KL. Rivaroxaban Failure in a Patient Taking Oxcarbazepine. Ann Pharmacother. 2021;55(10):1302–1303. doi: 10.1177/1060028021990374
   PubMed Web of Science ®Google Scholar
• Serra W, Li Calzi M, Coruzzi P. Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation. Clin Pract. 2015;5(3):788. doi: 10.4081/cp.2015.788
   PubMed Web of Science ®Google Scholar
• Langenbruch L, Meuth SG, Wiendl H, et al. Clinically relevant interaction of rivaroxaban and valproic acid - a case report. Seizure. 2020;80:46–47. doi: 10.1016/j.seizure.2020.05.024
   PubMed Web of Science ®Google Scholar
• Stöllberger C, Finsterer J. Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state. Heart & Lung. 2014;43(3):262–263. doi: 10.1016/j.hrtlng.2014.03.004
   PubMed Web of Science ®Google Scholar
• Grymonprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722–730. doi: 10.1093/ehjcvp/pvad070
   PubMed Web of Science ®Google Scholar
• Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Sci Rep. 2023;13(1):9257. doi: 10.1038/s41598-023-33876-8
   PubMed Web of Science ®Google Scholar
• Menichelli D, Pastori D, Pignatelli P, et al. Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report. Eur Heart J Case Rep. 2023;7(1):ytad006. doi: 10.1093/ehjcr/ytad006
   PubMedGoogle Scholar
• Paciullo F, Costa C, Gresele P. Rivaroxaban plasma levels and Levetiracetam: a case report. Ann Intern Med. 2020;173(1):71–72. doi: 10.7326/L19-0712
   PubMed Web of Science ®Google Scholar
• Lin SY, Tang SC, Tsai LK, et al. Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy. J Formos Med Assoc. 2020;119(12):1799–1806. doi: 10.1016/j.jfma.2020.02.003
   PubMed Web of Science ®Google Scholar
• Ho CJ, Chen SH, Lin CH, et al. Non-vitamin K oral anticoagulants and anti-seizure medications: a retrospective cohort study. Front Neurol. 2021;11:588053. doi: 10.3389/fneur.2020.588053
   PubMed Web of Science ®Google Scholar
• Manis MM, Petersen K, Roberts MZ, et al. Managing the drug-drug interaction with apixaban and Primidone: a case report. Hosp Pharm. 2023;58(4):345–349. doi: 10.1177/00185787221150928
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Scuto S, Marino E, et al. Anticoagulants and osteoporosis. Int J Mol Sci. 2019;20(21):5275. doi: 10.3390/ijms20215275
   PubMed Web of Science ®Google Scholar
• Thompson LE, Davis BH, Narayan R, et al. Personalizing direct oral anticoagulant therapy for a diverse population: role of race, kidney function, drug interactions, and pharmacogenetics. Clin Pharmacol Ther. 2023;113(3):585–599. doi: 10.1002/cpt.2714
   PubMed Web of Science ®Google Scholar
• McGregor IS, Cairns EA, Abelev S, et al. Access to cannabidiol without a prescription: a cross-country comparison and analysis. Int J Drug Policy. 2020;85:102935. doi: 10.1016/j.drugpo.2020.102935
   PubMed Web of Science ®Google Scholar
• Goodman S, Wadsworth E, Schauer G, et al. Use and perceptions of Cannabidiol Products in Canada and in the United States. Cannabis Cannabinoid Res. 2022;7(3):355–364. doi: 10.1089/can.2020.0093
   PubMedGoogle Scholar
• Guenoun M, Cohen S, Villaceque M, et al. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF. Europace. 2023;25(10):euad302. doi: 10.1093/europace/euad302
   PubMed Web of Science ®Google Scholar
• Yamashita T, Suzuki S, Inoue H, et al. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the all Nippon AF in the elderly (ANAFIE) registry. Eur Heart J Qual Care Clin Outcomes. 2022;8(2):202–213. doi: 10.1093/ehjqcco/qcab025
   PubMed Web of Science ®Google Scholar
• Essien UR, Chiswell K, Kaltenbach LA, et al. Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation: findings from the get with the guidelines-atrial fibrillation registry. JAMA Cardiol. 2022;7:1207–1217. doi: 10.1001/jamacardio.2022.3704
   PubMed Web of Science ®Google Scholar
• Bayer V, Kotalczyk A, Kea B, et al. Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF phase III registry. J Am Heart Assoc. 2022;11(6):e023907. doi: 10.1161/JAHA.121.023907
   PubMed Web of Science ®Google Scholar
• Platzbecker K, Müller-Fielitz H, Foraita R, et al. In atrial fibrillation epilepsy risk differs between oral anticoagulants: active comparator, nested case-control study. Europace. 2023;25(5):euad087. doi: 10.1093/europace/euad087
   PubMed Web of Science ®Google Scholar
• Carollo M, Crisafulli S, Ciccimarra F, et al. Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants. Expert Opin Drug Metab Toxicol. 2024;20(3):157–164. doi: 10.1080/17425255.2024.2322134
   PubMed Web of Science ®Google Scholar
• Dimakos J, Douros A. Methodological considerations on the Use of Cohort Designs in drug-drug interaction studies in pharmacoepidemiology. Curr Epidemiol Rep. 2024. doi: 10.1007/s40471-024-00347-1
   Google Scholar
• Hennessy S, Leonard CE, Gagne JJ, et al. Pharmacoepidemiologic Methods for Studying the Health effects of drug–drug interactions. Clin Pharma And Therapeutics. 2016;99(1):92–100. doi: 10.1002/cpt.277
   PubMed Web of Science ®Google Scholar
• Van der Linden L, Hias J, Vanassche T. The value and limitations of new oral anticoagulant plasma level assessments. Eur Heart J Suppl. 2022;24(Suppl A):A32–41. doi: 10.1093/eurheartj/suab153
   PubMedGoogle Scholar